

500 Chipeta Way, Salt Lake City, Utah 84108-1221

phone: 801-583-2787, toll free: 800-522-2787

Jonathan R. Genzen, MD, PhD, Chief Medical Officer

Patient Age/Sex:

Unknown

Specimen Collected: 21-Jun-23 09:06**Clozapine and Metabolites, S/P, Quant** | **Received: 21-Jun-23 09:06** | **Report/Verified: 21-Jun-23 09:09**

Procedure	Result	Units	Reference Interval
Clozapine, S/P, Quant	1267 ⁱ¹	ng/mL	
Norclozapine, S/P, Quant	598	ng/mL	
Clozapine-N-Oxide, S/P, Quant	132	ng/mL	
Total Clozapine and Metabolites	1997 #	ng/mL	[<=1500]

Test Information

i1: Clozapine, S/P, Quant

INTERPRETIVE INFORMATION: Clozapine and Metabolites, S/P, Quant

Therapeutic ranges are not well established. Clozapine is metabolized to norclozapine and clozapine-N-oxide. Clozapine concentrations between 100 and 700 ng/mL may correlate more with clinical response; however, non-responsiveness may also occur within this range. For refractory schizophrenia, clozapine concentrations greater than 350 ng/mL are suggested to achieve a therapeutic response.

Toxicity: Adverse effects to clozapine therapy may include tachycardia, drowsiness, hypotension, and seizures.

Therapeutic and toxic ranges are not well established in children.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:**ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-172-900035**Report Request ID:** 17766116**Printed:** 23-Jun-23 15:07

Page 1 of 1